Some of the earliest cancer vaccines used tumor cells; in 1993, promising preclinical results were reported from lethally irradiated tumor cells genetically engineered to secrete granulocyte‐macrophage colony‐stimulating factor (GM‐CSF).7 This evidence concerns the gene CSF2 and neoplasm.